Issue #19 · The Weekly Summary

Week 19 · May 5–11, 2026

Three major deals totaling $890M. Relay's RLY-2608 enters Phase 3. Recursion guides down. The 10 most important AI drug-discovery papers of the week — ranked.

Top 3 Deals

Insilico Medicine / Qilu Pharmaceutical · $120M

Exclusive Greater China licensing of a preclinical USP1 inhibitor for oncology.

Recursion / Roche-Genentech · $150M

Expanded neuroscience collaboration — three undisclosed CNS targets via phenomics.

Relay Therapeutics · RLY-2608 Phase 3

Pivotal study launched in HR+/HER2− breast cancer; interim readout expected 1H 2027.

Top 3 Papers

Pocket-aware flow matching for 10⁹-compound generative chemistry

Nguyen et al. · Nature · SOTA binding-pose RMSD with synthesizable scaffolds.

Allosteric PROTAC linker design via contrastive models

Li, Okafor, Shah · Nat. Chem. Biol. · 14 novel PROTACs with <100 nM DC50.

ProteinMPNN-X: zero-shot enzyme design with catalytic tetrads

Watson, Zhang, Baker · Science · 40% hit rate without directed evolution.

Stock Highlight

Top Mover

RXRX · Recursion

Weekly Δ

−8.1%

The sector sells off ahead of Q1 earnings as investors re-price phenomics-driven pipelines. SDGR and ABSI follow down; LLY and ROG catch the defensive bid.

This Week's Analysis

Why 0-to-DC Data Is the New Moat in AI Drug Discovery

The hardest dataset in drug discovery is not genomic or chemical — it's the longitudinal record of what a molecule actually did from target nomination through development candidate. Every failed assay, every SAR iteration, every off-target surprise is tacit knowledge that platform-only companies cannot bootstrap from public data...

Continue reading →

Read Full Report → Subscribe for Weekly Updates